In particular, memantine is now widely used since its approval by the FDA for the treatment of moderate-severe Alzheimer’s disease, as monotherapy or combined with acetylcholinesterase inhibitors [48,49,50]. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.